XML 51 R36.htm IDEA: XBRL DOCUMENT
v3.23.2

Collaborative Research, Development, and License Agreements - Additional Information (Detail) - USD ($) |  |  | 1 Months Ended | 12 Months Ended |  |  |
--- | --- | --- | --- | --- | --- | --- | ---
Dec. 05, 2022 | Feb. 22, 2022 | Mar. 31, 2022 | Jan. 31, 2022 | May 31, 2011 | Mar. 31, 2009 | Mar. 31, 2023 | Mar. 31, 2022 | Mar. 31, 2016 | Mar. 31, 2015 | Mar. 31, 2014
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Total Revenues |  | $ 1,500,000 |  |  |  |  | $ 370,000 | $ 1,500,000 |  |  |
Licensing Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Amortization expense of licenses |  |  |  |  |  |  | $ 82,000 | 14,000 |  |  |
Weighted average remaining amortization period for all licenses |  |  |  |  |  |  | 2 years |  |  |  |
Annual amortization expense of licenses year 1 |  |  |  |  |  |  | $ 3,000 |  |  |  |
Annual amortization expense of licenses year 2 |  |  |  |  |  |  | 3,000 |  |  |  |
Annual amortization expense of licenses year 3 |  |  |  |  |  |  | 3,000 |  |  |  |
Annual amortization expense of licenses year 4 |  |  |  |  |  |  | 3,000 |  |  |  |
Annual amortization expense of licenses year 5 |  |  |  |  |  |  | 3,000 |  |  |  |
BICO Group AB [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Nonrefundable upfront fee paid |  | 1,500,000 |  |  |  |  |  |  |  |  |
Total Revenues |  | $ 1,500,000 |  |  |  |  | 370,000 |  |  |  |
University of Missouri [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalty fees percentage minimum |  |  |  |  |  | 1.00% |  |  |  |  |
Royalty fees percentage maximum |  |  |  |  |  | 3.00% |  |  |  |  |
Minimum annual royalty paid |  |  |  | $ 25,000 |  |  |  |  |  |  |
Excess of minimum annual royalties payment |  |  | $ 0 |  |  |  | 0 |  |  |  |
Upfront payment | $ 50,000,000 |  |  |  |  |  | $ 0 |  |  |  |
University of Missouri [Member] | Sublicense Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty revenue from sublicensee |  |  |  |  |  |  | 3.00% |  |  |  |
Clemson University [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Minimum annual royalty paid |  |  |  |  |  |  | $ 40,000 | $ 40,000 |  |  |
Upfront payment |  |  |  |  |  |  | $ 0 |  |  |  |
Minimum annual royalty payment due |  |  |  |  |  |  |  |  | $ 40,000 | $ 20,000 | $ 20,000
Clemson University [Member] | Sublicense Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Percentage of royalty revenue from sublicensee |  |  |  |  |  |  | 40.00% |  |  |  |
Clemson University [Member] | Licensing Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalty fees percentage minimum |  |  |  |  | 1.50% |  |  |  |  |  |
Royalty fees percentage maximum |  |  |  |  | 3.00% |  |  |  |  |  |
Expected expiration year of license agreement |  |  |  |  | 2024-05 |  |  |  |  |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Royalty fees percentage minimum |  |  |  |  |  |  | 1.00% |  |  |  |
Royalty fees percentage maximum |  |  |  |  |  |  | 1.125% |  |  |  |
Percentage of sublicensing revenue |  |  |  |  |  |  | 3.50% |  |  |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] | 45 days of Dosing of First Patient in a Phase III Clinical Trial [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  | $ 500,000 |  |  |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] | 45 days of FDA Approval of First Licensed Product [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  | 1,000,000 |  |  |  |
Salk Institute for Biological Studies [Member] | Licensing Agreements [Member] | 45 Days of First Commercial Sale of Licensed Product in Territory [Member] |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |  |  |  |  |  |  |  |
Milestone payments |  |  |  |  |  |  | $ 1,500,000 |  |  |  |

X
- Definition Excess of minimum annual royalties payment. + References No definition available. + Details
Name: | onvo_ExcessOfMinimumAnnualRoyaltiesPayment
Namespace Prefix: | onvo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition License agreement expiration month. + References No definition available. + Details
Name: | onvo_LicenseAgreementExpirationMonth
Namespace Prefix: | onvo_
Data Type: | xbrli:gYearMonthItemType
Balance Type: | na
Period Type: | duration

X
- Definition Milestone payments. + References No definition available. + Details
Name: | onvo_MilestonePayments
Namespace Prefix: | onvo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Minimum annual royalty payment. + References No definition available. + Details
Name: | onvo_MinimumAnnualRoyaltyPayment
Namespace Prefix: | onvo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Nonrefundable upfront fee paid. + References No definition available. + Details
Name: | onvo_NonrefundableUpfrontFeePaid
Namespace Prefix: | onvo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of royalty revenue from sublicensee. + References No definition available. + Details
Name: | onvo_PercentageOfRoyaltyRevenueFromSublicensee
Namespace Prefix: | onvo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of sublicensing revenue. + References No definition available. + Details
Name: | onvo_PercentageOfSublicensingRevenue
Namespace Prefix: | onvo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty fees percentage maximum. + References No definition available. + Details
Name: | onvo_RoyaltyFeesPercentageMaximum
Namespace Prefix: | onvo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty fees percentage minimum. + References No definition available. + Details
Name: | onvo_RoyaltyFeesPercentageMinimum
Namespace Prefix: | onvo_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Royalty payments under license agreement due year two. + References No definition available. + Details
Name: | onvo_RoyaltyPaymentsUnderLicenseAgreementDueYearTwo
Namespace Prefix: | onvo_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Upfront fee payment. + References No definition available. + Details
Name: | onvo_UpfrontFeePayment
Namespace Prefix: | onvo_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 28 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -URI https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Weighted average period before the next renewal or extension (both explicit and implicit) for intangible assets that have been renewed or extended, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (d)(2) -URI https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetWeightedAveragePeriodBeforeNextRenewalOrExtension
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the next rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fifth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFive
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the fourth rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the third rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized in the second rolling twelve months following the latest balance sheet. For interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date. + References No definition available. + Details
Name: | us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 4 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 924 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -URI https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856 + Details
Name: | us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onvo_BICOGroupABMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onvo_UniversityOfMissouriMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=onvo_SublicenseAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onvo_ClemsonUniversityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=onvo_SalkInstituteForBiologicalStudiesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=onvo_DaysOfTheDosingOfTheFirstPatientInAPhaseIiiClinicalTrialMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=onvo_DaysOfFdaApprovalOfFirstLicensedProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=onvo_DaysOfFirstCommercialSaleOfALicensedProductInTerritoryMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |